Skip to main content
SpringerLink
Log in

Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Graft-versus-host disease (GVHD) remains a major obstacle to allogeneic bone marrow transplantation. We administered cyclosporin A (CsA) by continuous intravenous infusion for prophylaxis against GVHD and adjusted the dose to maintain a constant whole blood level. Forty-five patients, ranging in age from 16 to 56, mean 39.5 years, undergoing allogeneic transplantation for various hematological malignancies received CsA as a continuous intravenous infusion. CsA was started on day −1 and continued until day +22 when oral CsA was initiated. The whole blood level of CsA was determined and the dose adjusted to maintain a fixed level. Methotrexate 15 mg/m2 i.v. was given on day +1, followed by 10 mg/m2 on days +3 and +6. CsA administered as a continuous infusion was well tolerated. All patients required multiple adjustments of the infused dose of CsA to maintain the targeted whole blood level. The mean rise in creatinine was 0.89 mg/dl. There was an association between the concomitant administration of amphotericin B and CsA and the development of nephrotoxicity. Hypertension developed in 30/45 patients, and all responded to oral nifedipine. Tremors were noted in 16/45 patients. None of the patients developed serious neurological side effects. Greater than grade-I acute GVHD developed in only 13% of the patients. We conclude that administering CsA as an adjusted dose by continuous intravenous infusion is well tolerated and effective in preventing acute GVHD in patients undergoing allogeneic bone marrow transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Deeg HJ, Storb R, Thomas ED, et al. (1985) Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute non-lymphoblastic leukemia. Blood 65:1325–1334

    PubMed  Google Scholar 

  2. Storb R, Deeg HJ, Thomas ED, et al. (1985) Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 66:698–702

    PubMed  Google Scholar 

  3. Beelen DW, Quabeck K, Kaiser B (1990) Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 50:421–427

    PubMed  Google Scholar 

  4. Tallman MS, Nemunaitis JJ, McGuire TR, et al. (1988) Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients. Transplantation 45:810–813

    PubMed  Google Scholar 

  5. Deeg HJ, Spitzer TR, Cottier-Fox M, Cahill R, Pickle LW (1991) Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 7:193–198

    PubMed  Google Scholar 

  6. Forman SJ, Blume KG, Krance RA, et al. (1987) A prospective randomized study of acute graft-versus-host disease in 107 patients with leukemia: methotrexate/prednisone vs cyclosporin A/prednisone. Transplant Proc 19:2605–2607

    PubMed  Google Scholar 

  7. Shepherd JD, Shore TB, Reece DE, et al. (1983) Cyclosporine and methylprednisolone for prophylaxis of acute graftversus-host disease. Bone Marrow Transplant 3:553–558

    Google Scholar 

  8. Kennedy MS, Yee GC, McGuire TR, Crowley JJ, et al. (1985) Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation 40:249–253

    PubMed  Google Scholar 

  9. Prepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R (1991) Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 7:461–465

    PubMed  Google Scholar 

  10. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ (1988) Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 319:65–70

    PubMed  Google Scholar 

  11. Santos GW, Tutschka PJ, Brookmeyer R, et al. (1987) Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1:21–28

    Google Scholar 

  12. Kahan BD, Van Buren CT, Lin SN, et al. (1982) Immunopharmacological monitoring of cyclosporin A-treated recipients of cadaveric kidney allografts. Transplant 34:36–45

    Google Scholar 

  13. Kahan BD, Reid M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15:446–453

    Google Scholar 

  14. Leson CL, Byron SM, Giesbrecht EE, Saunders EF (1989) Therapeutic monitoring of cyclosporine following pediatric bone marrow transplantation: problems with sampling from silicone central venous lines. Ann Pharmacother 23:300–303

    Google Scholar 

  15. Schran HP, Rosano TG, Hassell AE, Pell MA (1987) Determination of cyclosporine with monoclonal antibodies. Clin Chem 33:2225–2228

    PubMed  Google Scholar 

  16. Thomas ED, Storb R, Cliff RA, et al. (1975) Bone marrow transplantation. N Engl J Med 292:832–843

    PubMed  Google Scholar 

  17. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. Am Statist Assoc 53:457–481

    Google Scholar 

  18. Storb R, Deeg HJ, Whitehead J, et al. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation. 314:729–735

    Google Scholar 

  19. Stockschlaeder M, Storb R, Pepe M, et al. (1992) A pilot study of low-dose cyclosporine for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 80:49–54

    PubMed  Google Scholar 

  20. Burckart GJ, Canafax D, Yee GC (1986) Cyclosporine monitoring. Drug Intell Clin Pharm 20:649–652

    PubMed  Google Scholar 

  21. Yee GC, Kennedy MS, Deeg HJ, Leonard TM, Thomas ED, Storb R (1985) Cyclosporine-associated renal dysfunction in marrow transplant recipients. Transplant Proc 17 [Suppl 1]:196–201

    PubMed  Google Scholar 

  22. Keown PA, Stiller CR, Laupacis AL, et al. (1983) The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 15:659

    Google Scholar 

  23. Barrett AJ, Kendra JR, Lucas CF, et al. (1982) Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J 285:162–166

    Google Scholar 

  24. Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A (1984) Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 38:34–37

    PubMed  Google Scholar 

  25. Feuten G, Mihatsch M (1992) Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326:1654–1660

    PubMed  Google Scholar 

  26. Schroeder TJ, Myre SA, Melvin DB, Van Der Bel Kahn J, et al. (1989) Efficacy and safety of constant-rate intravenous cyclosporine infusion immediately after heart transplantation. J Heart Transpl 8:5–10

    Google Scholar 

  27. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED (1983) Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 35:211–215

    PubMed  Google Scholar 

  28. Sawaya BP, Weihprecht H, Campbell WR, Lorenz JN, Webb RC, Briggs JP, Schnermann J (1991) Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 87:2097–2107

    PubMed  Google Scholar 

  29. Goldberg HJ, Wong PY, Cole EH, Levy GA, Skorecki KL (1989) Dissociation between the immunosuppressive activity of cyclosporine derivatives and their effects on intracellular calcium signaling in mesangial cells. Transplantation 47:731–733

    PubMed  Google Scholar 

  30. Tolins JP, Raij L (1988) Adverse effect of amphotericin B administration on renal hemodynamics in the rat: neurohumoral mechanisms and influence of calcium channel blockade. J Pharmacol Exp Ther 245:594–599

    PubMed  Google Scholar 

  31. Degroen PC (1990) Cyclosporine and the liver: how one affects the other. Transplant Proc 22:1197–1202

    PubMed  Google Scholar 

  32. Kahan BD, Shaw LM, Holt D, Grevel J, Johnson A (1990) Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 36:1510–1516

    PubMed  Google Scholar 

  33. von Bueltzingloewen A, Belanger R, Perrealut C, et al. (1993) Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. Blood 81:849–855

    PubMed  Google Scholar 

  34. Kahan BD (1989) Cyclosporine. N Engl J Med 321:1725–1737

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Bone Marrow Transplant Unit, Division of Hematology/Oncology, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, MA, USA

    K. B. Miller, D. P. Schenkein, R. Comenzo, J. K. Erban, T. Fogaren, C. A. Hirsch, E. Berkman & A. Rabson

Authors
  1. K. B. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. P. Schenkein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Comenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. K. Erban
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Fogaren
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. A. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Berkman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Rabson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, K.B., Schenkein, D.P., Comenzo, R. et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 68, 15–20 (1994). https://doi.org/10.1007/BF01695914

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01695914

Keywords

Search

Navigation